Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats

References

• Tham YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89(9):1401–1438. doi:10.1007/s00204-015-1477-x25708889
   PubMed Web of Science ®Google Scholar
• Jackson JD, Cotton SE, Bruce Wirta S, et al. Burden of heart failure on patients from China: results from a cross-sectional survey. Drug Des Devel Ther. 2018;12:1659–1668. doi:10.2147/DDDT.S148949
   PubMed Web of Science ®Google Scholar
• Liehn EA, Postea O, Curaj A, Marx N. Repair after myocardial infarction between fantasy and reality. J Am Coll Cardiol. 2011;58(23):2357–2362. doi:10.1016/j.jacc.2011.08.03422115639
   PubMed Web of Science ®Google Scholar
• Cohn JN, Ferrari R, Sharpe N; Behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35(3):569–582. doi:10.1016/s0735-1097(99)00630-010716457
   PubMed Web of Science ®Google Scholar
• Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation. 2007;115(12):1563–1570. doi:10.1161/CIRCULATIONAHA.106.66681817353436
   PubMed Web of Science ®Google Scholar
• Wu QQ, Xiao Y, Yuan Y, et al. Mechanisms contributing to cardiac remodeling. Clin Sci (Lond). 2017;131(18):2319–2345. doi:10.1042/CS2017116728842527
   PubMed Web of Science ®Google Scholar
• Suthahar N, Meijers WC, Silljé HHW, de Boer RA. From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodeling and perspectives on differential treatment opportunities. Curr Heart Fail Rep. 2017;14(4):235–250. doi:10.1007/s11897-017-0343-y28707261
   PubMedGoogle Scholar
• Bacmeister L, Schwarzl M, Warnke S, et al. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114(3):19–54. doi:10.1007/s00395-019-0722-530887214
   PubMed Web of Science ®Google Scholar
• Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 2019;33(2):363–382. doi:10.1111/jvim.1545430806496
   PubMed Web of Science ®Google Scholar
• Côté N, Mahmut A, Fournier D, et al. Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease. Pathobiology. 2014;81(1):15–24. doi:10.1159/00035089623969418
   PubMed Web of Science ®Google Scholar
• Müller P, Kazakov A, Semenov A, et al. Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs. J Cardiovasc Pharmacol Ther. 2013;18(1):87–93. doi:10.1177/107424841143477322368266
   PubMed Web of Science ®Google Scholar
• Zhang LH, Pang XF, Bai F, et al. Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1/AT2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. Cardiovasc Drugs Ther. 2015;29(3):243–255. doi:10.1007/s10557-015-6592-725994830
   PubMed Web of Science ®Google Scholar
• Zhang WW, Bai F, Wang J, et al. Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor. Drug Des Devel Ther. 2017;11:3019–3033. doi:10.2147/DDDT.S144807
   PubMed Web of Science ®Google Scholar
• Crowley MJ, Powers BJ, Myers ER, McBroom AJ, Sanders G. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: future research needs prioritization. Am Heart J. 2012;163:777–782. doi:10.1016/j.ahj.2012.02.01622607854
   PubMed Web of Science ®Google Scholar
• Ram CVS. Angiotensin receptor blockers: current status and future prospects. Am J Med. 2008;121:656–663. doi:10.1016/j.amjmed.2008.02.03818691475
   PubMed Web of Science ®Google Scholar
• Pabreja K, Mohd MA, Kode C, Wootten D, Furness SGB. Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. Br J Pharmacol. 2014;171:1114–1128. doi:10.1111/bph.1231323889512
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Chen L, et al. Glucagon-like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway. J Diabetes Res. 2013;2013(5):1–8.
   Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa160382727295427
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M, DeFronzo RA, Del Prato S, et al. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? Diabetes Care. 2017;40(7):813–820. doi:10.2337/dc16-273628637886
   PubMed Web of Science ®Google Scholar
• Svanström H, Ueda P, Melbye M, et al. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes Endocrinol. 2019;7(2):106–114. doi:10.1016/S2213-8587(18)30320-630527909
   PubMed Web of Science ®Google Scholar
• Bai F, Pang XF, Zhang LH, et al. Angiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44–hyaluronan interaction in rats with hypertension and myocardial fibrosis. Life Sci. 2016;153:141–152. doi:10.1016/j.lfs.2016.04.01327085217
   PubMed Web of Science ®Google Scholar
• Meyers TA, Heitzman JA, Krebsbach AM, et al. Acute AT1R blockade prevents isoproterenol-induced injury in mdx hearts. J Mol Cell Cardiol. 2019;128:51–61. doi:10.1016/j.yjmcc.2019.01.01330664850
   PubMed Web of Science ®Google Scholar
• Jones ES, Black MJ, Widdop RE. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol. 2004;37(5):1023–1030. doi:10.1016/j.yjmcc.2004.08.00415522279
   PubMed Web of Science ®Google Scholar
• Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT2 receptor and tissue injury: therapeutic implications. Curr Hypertens Res. 2014;16:416–426. doi:10.1007/s11906-013-0416-6
   PubMed Web of Science ®Google Scholar
• Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M, Oshima T. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life Sci. 2006;80(1):82–88. doi:10.1016/j.lfs.2006.08.03317023005
   PubMed Web of Science ®Google Scholar
• Perret-Guillaume C, Joly L, Jankowski P, Benetos A. Benefits of the RAS blockade: clinical evidence before the ONTARGET study. J Hypertens Suppl. 2009;27(2):S3–S7. doi:10.1097/01.hjh.0000354511.14086.f1
   PubMedGoogle Scholar
• Minas JN, Thorwald MA, Conte D, Vázquez-Medina JP, Nishiyama A, Ortiz RM. Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. Clin Exp Pharmacol Physiol. 2015;42(11):1178–1188. doi:10.1111/1440-1681.1247326234762
   PubMed Web of Science ®Google Scholar
• Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1–7). Cardiovasc Res. 2007;73(3):463–469. doi:10.1016/j.cardiores.2006.09.00617049503
   PubMed Web of Science ®Google Scholar
• Wang W, McKinnie SM, Farhan M, et al. Angiotensin-converting enzyme 2 metabolizes and partially inactivates Pyr-Apelin-13 and Apelin-17: physiological effects in the cardiovascular system. Hypertension. 2016;68(2):365–377. doi:10.1161/HYPERTENSIONAHA.115.0689227217402
   PubMed Web of Science ®Google Scholar
• Zhang W, Miao J, Wang S, Zhang Y. The protective effects of beta-casomorphin-7 against glucose -induced renal oxidative stress in vivo and vitro. PLoS One. 2013;8(5):e63472. doi:10.1371/journal.pone.006347223658831
   PubMed Web of Science ®Google Scholar
• Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822–828. doi:10.1038/nature0078612075344
   PubMed Web of Science ®Google Scholar
• Wang X, Ye Y, Gong H, et al. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1–7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol. 2016;97:180–190. doi:10.1016/j.yjmcc.2016.05.01227210827
   PubMed Web of Science ®Google Scholar
• Fabiani I, Pugliese NR, La Carrubba S, et al. Incremental prognostic value of a complex left ventricular remodeling classification in asymptomatic for heart failure hypertensive patients. J Am Soc Hypertens. 2017;11(7):412–419. doi:10.1016/j.jash.2017.05.00528619598
   PubMed Web of Science ®Google Scholar
• Forrester SJ, Booz GW, Sigmund CD, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018;98(3):1627–1738. doi:10.1152/physrev.00038.201729873596
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Giamouzis G, Boudoulas KD, et al. Left ventricular geometry as a major determinant of left ventricular ejection fraction: physiological considerations and clinical implications. Eur J Heart Fail. 2018;20(3):436–444. doi:10.1002/ejhf.105529105899
   PubMed Web of Science ®Google Scholar
• Fabijanovic D, Milicic D, Cikes M. Left ventricular size and ejection fraction: are they still relevant? Heart Fail Clin. 2019;15(2):147–158. doi:10.1016/j.hfc.2018.12.01230832807
   PubMed Web of Science ®Google Scholar
• Tomoaia R, Beyer RS, Simu G, Serban AM, Pop D. Understanding the role of echocardiography in remodeling after acute myocardial infarction and development of heart failure with preserved ejection fraction. Med Ultrason. 2019;21(1):69–76. doi:10.11152/mu-176830779834
   PubMed Web of Science ®Google Scholar
• Esposito G, Cappetta D, Russo R, et al. Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. Br J Pharmacol. 2017;174(22):4070–4086. doi:10.1111/bph.1368627922176
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849–870. doi:10.1161/CIRCULATIONAHA.117.02813628847797
   PubMed Web of Science ®Google Scholar
• Gaspari T, Brdar M, Lee HW, et al. Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis. Diab Vasc Dis Res. 2016;13(1):56–68. doi:10.1177/147916411560500026408644
   PubMed Web of Science ®Google Scholar